Glycoprotein-specific antibodies produced by DNA vaccination protect guinea pigs from lethal Argentine and Venezuelan hemorrhagic fever

Journal of Virology

Volumn 90, Issue 7, 2016, Pages 3515-3529

  Golden, Joseph W ^a   Maes, Piet ^b   Kwilas, Steven A ^a   Ballantyne, John ^c   Hooper, Jay W ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c Aldevron LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DNA VACCINE; GLYCOPROTEIN SPECIFIC ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS GLYCOPROTEIN 1; VIRUS GLYCOPROTEIN 2; GLYCOPROTEIN; IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARENAVIRUS; ARGENTINE HEMORRHAGIC FEVER; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DNA IMMUNIZATION; DRUG EFFICACY; FEMALE; GUANARITO VIRUS; GUINEA PIG; INFECTION PREVENTION; JUNIN VIRUS; MACHUPO VIRUS; NONHUMAN; PLAQUE REDUCTION NEUTRALIZATION TEST; PRIORITY JOURNAL; RABBIT; SABIA VIRUS; SURVIVAL; VENEZUELAN HEMORRHAGIC FEVER; VIREMIA; VIRUS NEUTRALIZATION; WEIGHT REDUCTION; ANIMAL; DISEASE MODEL; HEMORRHAGIC FEVER, AMERICAN; IMMUNOLOGY; NEW WORLD ARENAVIRUS; PASSIVE IMMUNIZATION; PROCEDURES; RABBITS AND HARES; SERODIAGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; ARENAVIRUSES, NEW WORLD; DISEASE MODELS, ANIMAL; FEMALE; GLYCOPROTEINS; GUINEA PIGS; HEMORRHAGIC FEVER, AMERICAN; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; NEUTRALIZATION TESTS; RABBITS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VACCINES, DNA;

EID: 84960968473     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02969-15     Document Type: Article

References (62)

1. Buchmeier MJ, de la Torre JC, Peters CJ. 2013. Arenaviridae, p 1283-1303. In Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin MA, Racaniello VR, Roizman B (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Charrel RN, Feldmann H, Fulhorst CF, Khelifa R, de Chesse R, de Lamballerie X. 2002. Phylogeny of New World arenaviruses based on the complete coding sequences of the small genomic segment identified an evolutionary lineage produced by intrasegmental recombination. Biochem Biophys Res Commun 296:1118-1124. http://dx.doi.org/10.1016/S0006-291X(02)02053-3.
3. Charrel RN, de Lamballerie X. 2003. Arenaviruses other than Lassa virus. Antiviral Res 57:89-100. http://dx.doi.org/10.1016/S0166-3542(02)00202-4.
4. Peters CJ. 2002. Human infection with arenaviruses in the Americas. Curr Top Microbiol Immunol 262:65-74.
5. Delgado S, Erickson BR, Agudo R, Blair PJ, Vallejo E, Albarino CG, Vargas J, Comer JA, Rollin PE, Ksiazek TG, Olson JG, Nichol ST. 2008. Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog 4:e1000047. http://dx.doi.org/10.1371/journal.ppat.1000047.
6. Gonzalez JP, Bowen MD, Nichol ST, Rico-Hesse R. 1996. Genetic characterization and phylogeny of Sabia virus, an emergent pathogen in Brazil. Virology 221:318-324. http://dx.doi.org/10.1006/viro.1996.0381.
7. Centers for Disease Control and Prevention. 2000. Fatal illnesses associated with a new world arenavirus-California, 1999-2000. MMWR Morb Mortal Wkly Rep 49:709-711.
8. Maiztegui JI, Fernandez NJ, de Damilano AJ. 1979. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet ii:1216-1217.
9. Monath TP. 1975. Lassa fever: review of epidemiology and epizootiology. Bull World Health Organ 52:577-592.
10. Stinebaugh BJ, Schloeder FX, Johnson KM, Mackenzie RB, Entwisle G, De Alba E. 1966. Bolivian hemorrhagic fever. A report of four cases. Am J Med 40:217-230.
11. Eddy GA, Wagner FS, Scott SK, Mahlandt BJ. 1975. Protection of monkeys against Machupo virus by the passive administration of Bolivian haemorrhagic fever immunoglobulin (human origin). Bull World Health Organ 52:723-727.
12. Jahrling PB, Peters CJ. 1984. Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain. Infect Immun 44:528-533.
13. Kenyon RH, Green DE, Eddy GA, Peters CJ. 1986. Treatment of Junin virus-infected guinea pigs with immune serum: development of late neurological disease. J Med Virol 20:207-218. http://dx.doi.org/10.1002/jmv.1890200303.
14. Enria DA, Briggiler AM, Sanchez Z. 2008. Treatment of Argentine hemorrhagic fever. Antiviral Res 78:132-139. http://dx.doi.org/10.1016/j.antiviral.2007.10.010.
15. Enria DA, Briggiler AM, Fernandez NJ, Levis SC, Maiztegui JI. 1984. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet ii:255-256.
16. Maiztegui JI, McKee KT, Jr, Barrera Oro JG, Harrison LH, Gibbs PH, Feuillade MR, Enria DA, Briggiler AM, Levis SC, Ambrosio AM, Halsey NA, Peters CJ. 1998. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J Infect Dis 177: 277-283. http://dx.doi.org/10.1086/514211.
17. Lenz O, Ter Meulen J, Klenk HD, Seidah NG, Garten W. 2001. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc Natl Acad Sci U S A 98:12701-12705. http://dx.doi.org/10.1073/pnas.221447598.
18. York J, Romanowski V, Lu M, Nunberg JH. 2004. The signal peptide of the Junin arenavirus envelope glycoprotein is myristoylated and forms an essential subunit of the mature G1-G2 complex. J Virol 78:10783-10792. http://dx.doi.org/10.1128/JVI.78.19.10783-10792.2004.
19. Burri DJ, da Palma JR, Kunz S, Pasquato A. 2012. Envelope glycoprotein of arenaviruses. Viruses 4:2162-2181. http://dx.doi.org/10.3390/v4102162.
20. Radoshitzky SR, Abraham J, Spiropoulou CF, Kuhn JH, Nguyen D, Li W, Nagel J, Schmidt PJ, Nunberg JH, Andrews NC, Farzan M, Choe H. 2007. Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature 446:92-96. http://dx.doi.org/10.1038/nature05539.
21. Sanchez A, Pifat DY, Kenyon RH, Peters CJ, McCormick JB, Kiley MP. 1989. Junin virus monoclonal antibodies: characterization and crossreactivity with other arenaviruses. J Gen Virol 70:1125-1132. http://dx.doi.org/10.1099/0022-1317-70-5-1125.
22. Parekh BS, Buchmeier MJ. 1986. Proteins of lymphocytic choriomeningitis virus: antigenic topography of the viral glycoproteins. Virology 153: 168-178. http://dx.doi.org/10.1016/0042-6822(86)90020-6.
23. Buchmeier MJ, Lewicki HA, Tomori O, Oldstone MB. 1981. Monoclonal antibodies to lymphocytic choriomeningitis and Pichinde viruses: generation, characterization, and cross-reactivity with other arenaviruses. Virology 113:73-85. http://dx.doi.org/10.1016/0042-6822(81)90137-9.
24. Bruns M, Cihak J, Muller G, Lehmann-Grube F. 1983. Lymphocytic choriomeningitis virus. VI. Isolation of a glycoprotein mediating neutralization. Virology 130:247-251.
25. Kutzler MA, Weiner DB. 2008. DNA vaccines: ready for prime time? Nat Rev Genet 9:776-788. http://dx.doi.org/10.1038/nrg2432.
26. Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, Nabel GJ. 2004. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428:561-564. http://dx.doi.org/10.1038/nature02463.
27. Hooper JW, Ferro AM, Golden JW, Silvera P, Dudek J, Alterson K, Custer M, Rivers B, Morris J, Owens G, Smith JF, Kamrud KI. 2009. Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine 28:494-511. http://dx.doi.org/10.1016/j.vaccine.2009.09.133.
28. Hooper JW, Josleyn M, Ballantyne J, Brocato R. 2013. A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate panhantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS). Vaccine 31:4314-4321. http://dx.doi.org/10.1016/j.vaccine.2013.07.025.
29. Golden JW, Zaitseva M, Kapnick S, Fisher RW, Mikolajczyk MG, Ballantyne J, Golding H, Hooper JW. 2011. Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease. Virol J 8:441. http://dx.doi.org/10.1186/1743-422X-8-441.
30. Hooper JW, Ferro AM, Wahl-Jensen V. 2008. Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus. J Virol 82:1332-1338. http://dx.doi.org/10.1128/JVI.01822-07.
31. Golden JW, Hooper JW. 2010. Evaluating the orthopoxvirus type I interferon-binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model. Clin Vaccine Immunol 17:1656-1665. http://dx.doi.org/10.1128/CVI.00235-10.
32. Webb PA, Johnson KM, Mackenzie RB. 1969. The measurement of specific antibodies in Bolivian hemorrhagic fever by neutralization of virus plaques. Proc Soc Exp Biol Med 130:1013-1019. http://dx.doi.org/10.3181/00379727-130-33711.
33. Kwilas S, Kishimori JM, Josleyn M, Jerke K, Ballantyne J, Royals M, Hooper JW. 2014. A hantavirus pulmonary syndrome (HPS) DNA vaccine delivered using a spring-powered jet injector elicits a potent neutralizing antibody response in rabbits and nonhuman primates. Curr Gene Ther 14:200-210. http://dx.doi.org/10.2174/1566523214666140522122633.
34. Ray N, Whidby J, Stewart S, Hooper JW, Bertolotti-Ciarlet A. 2010. Study of Andes virus entry and neutralization using a pseudovirion system. J Virol Methods 163:416-423. http://dx.doi.org/10.1016/j.jviromet.2009.11.004.
35. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
36. Candurra NA, Damonte EB, Coto CE. 1989. Antigenic relationships between attenuated and pathogenic strains of Junin virus. J Med Virol 27:145-150. http://dx.doi.org/10.1002/jmv.1890270215.
37. Cresta B, Padula P, de Martinez Segovia M. 1980. Biological properties of Junin virus proteins. I. Identification of the immunogenic glycoprotein. Intervirology 13:284-288.
38. Kenyon RH, Condie RM, Jahrling PB, Peters CJ. 1990. Protection of guinea pigs against experimental Argentine hemorrhagic fever by purified human IgG: importance of elimination of infected cells. Microb Pathog 9:219-226. http://dx.doi.org/10.1016/0882-4010(90)90010-N.
39. Weissenbacher MC, Coto CE, Calello MA. 1975. Cross-protection between Tacaribe complex viruses. Presence of neutralizing antibodies against Junin virus (Argentine hemorrhagic fever) in guinea pigs infected with Tacaribe virus. Intervirology 6:42-49.
40. Lopez N, Scolaro L, Rossi C, Jacamo R, Candurra N, Pujol C, Damonte EB, Franze-Fernandez MT. 2000. Homologous and heterologous glycoproteins induce protection against Junin virus challenge in guinea pigs. J Gen Virol 81:1273-1281. http://dx.doi.org/10.1099/0022-1317-81-5-1273.
41. Seregin AV, Yun NE, Poussard AL, Peng BH, Smith JK, Smith JN, Salazar M, Paessler S. 2010. TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs. Vaccine 28:4713-4718. http://dx.doi.org/10.1016/j.vaccine.2010.04.077.
42. Sommerstein R, Flatz L, Remy MM, Malinge P, Magistrelli G, Fischer N, Sahin M, Bergthaler A, Igonet S, Ter Meulen J, Rigo D, Meda P, Rabah N, Coutard B, Bowden TA, Lambert PH, Siegrist CA, Pinschewer DD. 2015. Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection. PLoS Pathog 11:e1005276. http://dx.doi.org/10.1371/journal.ppat.1005276.
43. Howard CR, Lewicki H, Allison L, Salter M, Buchmeier MJ. 1985. Properties and characterization of monoclonal antibodies to Tacaribe virus. J Gen Virol 66:1383-1395. http://dx.doi.org/10.1099/0022-1317-66-7-1383.
44. Ruo SL, Mitchell SW, Kiley MP, Roumillat LF, Fisher-Hoch SP, Mc-Cormick JB. 1991. Antigenic relatedness between arenaviruses defined at the epitope level by monoclonal antibodies. J Gen Virol 72:549-555. http://dx.doi.org/10.1099/0022-1317-72-3-549.
45. Weber EL, Buchmeier MJ. 1988. Fine mapping of a peptide sequence containing an antigenic site conserved among arenaviruses. Virology 164: 30-38. http://dx.doi.org/10.1016/0042-6822(88)90616-2.
46. Buchmeier MJ, Lewicki HA, Tomori O, Johnson KM. 1980. Monoclonal antibodies to lymphocytic choriomeningitis virus react with pathogenic arenaviruses. Nature 288:486-487. http://dx.doi.org/10.1038/288486a0.
47. Buchmeier MJ, Elder JH, Oldstone MB. 1978. Protein structure of lymphocytic choriomeningitis virus: identification of the virus structural and cell associated polypeptides. Virology 89:133-145. http://dx.doi.org/10.1016/0042-6822(78)90047-8.
48. Howard CR. 1987. Neutralization of arenaviruses by antibody. Curr Top Microbiol Immunol 134:117-130.
49. Martinez Peralta LA, Coto CE, Weissenbacher MC. 1993. The Tacaribe complex, p 281-298. In Salvato M (ed), The Arenaviridae. Plenum Press, New York, NY.
50. Peters CJ, Jahrling PB, Liu CT, Kenyon RH, McKee KT, Jr, Barrera Oro JG. 1987. Experimental studies of arenaviral hemorrhagic fevers. Curr Top Microbiol Immunol 134:5-68.
51. Golden JW, Hammerbeck CD, Mucker EM, Brocato RL. 2015. Animal models for the study of rodent-borne hemorrhagic fever viruses: arenaviruses and hantaviruses. Biomed Res Int 2015:793257. http://dx.doi.org/10.1155/2015/793257.
52. Wright KE, Buchmeier MJ. 1991. Antiviral antibodies attenuate T-cellmediated immunopathology following acute lymphocytic choriomeningitis virus infection. J Virol 65:3001-3006.
53. Hall WC, Geisbert TW, Huggins JW, Jahrling PB. 1996. Experimental infection of guinea pigs with Venezuelan hemorrhagic fever virus (Guanarito): a model of human disease. Am J Trop Med Hyg 55:81-88.
54. Peters CJ, Kuehne RW, Mercado RR, Le Bow RH, Spertzel RO, Webb PA. 1974. Hemorrhagic fever in Cochabamba, Bolivia, 1971. Am J Epidemiol 99:425-433.
55. Bell TM, Bunton TE, Shaia CI, Raymond JW, Honnold SP, Donnelly GC, Shamblin JD, Wilkinson ER, Cashman KA. 2016. Pathogenesis of Bolivian hemorrhagic fever in guinea pigs. Vet Pathol 53:190-199. http://dx.doi.org/10.1177/0300985815588609.
56. Briese T, Paweska JT, McMullan LK, Hutchison SK, Street C, Palacios G, Khristova ML, Weyer J, Swanepoel R, Egholm M, Nichol ST, Lipkin WI. 2009. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog 5:e1000455. http://dx.doi.org/10.1371/journal.ppat.1000455.
57. Kenyon RH, Canonico PG, Green DE, Peters CJ. 1986. Effect of ribavirin and tributylribavirin on Argentine hemorrhagic fever (Junin virus) in guinea pigs. Antimicrob Agents Chemother 29:521-523. http://dx.doi.org/10.1128/AAC.29.3.521.
58. Matsushita H, Sano A, Wu H, Jiao JA, Kasinathan P, Sullivan EJ, Wang Z, Kuroiwa Y. 2014. Triple immunoglobulin gene knockout transchromosomic cattle: bovine lambda cluster deletion and its effect on fully human polyclonal antibody production. PLoS One 9:e90383. http://dx.doi.org/10.1371/journal.pone.0090383.
59. Hooper JW, Brocato RL, Kwilas SA, Hammerbeck CD, Josleyn MD, Royals M, Ballantyne J, Wu H, Jiao JA, Matsushita H, Sullivan EJ. 2014. DNA vaccine-derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome. Sci Transl Med 6:264ra162. http://dx.doi.org/10.1126/scitranslmed.3010082.
60. Bounds CE, Kwilas SA, Kuehne AI, Brannan JM, Bakken RR, Dye JM, Hooper JW, Dupuy LC, Ellefsen B, Hannaman D, Wu H, Jiao JA, Sullivan EJ, Schmaljohn CS. 2015. Human polyclonal antibodies produced through DNA vaccination of transchromosomal cattle provide mice with post-exposure protection against lethal Zaire and Sudan ebolaviruses. PLoS One 10:e0137786. http://dx.doi.org/10.1371/journal.pone.0137786.
61. Kugelman JR, Kugelman-Tonos J, Ladner JT, Pettit J, Keeton CM, Nagle ER, Garcia KY, Froude JW, Kuehne AI, Kuhn JH, Bavari S, Zeitlin L, Dye JM, Olinger GG, Sanchez-Lockhart M, Palacios GF. 2015. Emergence of Ebola virus escape variants in infected nonhuman primates treated with the MB-003 antibody cocktail. Cell Rep 12:2111-2120. http://dx.doi.org/10.1016/j.celrep.2015.08.038.
62. Alche LE, Coto CE. 1988. Differentiation of Junin virus and antigenic variants isolated in vivo by kinetic neutralization assays. J Gen Virol 69: 2123-2127. http://dx.doi.org/10.1099/0022-1317-69-8-2123.